Company

Tetraneuron S.L.

Tetraneuron develops gene therapies and a biomarker for Alzheimer's and other neurodegenerative diseases.

About

Tetraneuron develops AAV-based E2F4DN gene therapies for Alzheimer's disease and other neurodegenerative conditions, along with an E2F4 biomarker for early detection of Alzheimer's. The company is a Cajal Institute (CSIC) spin-off founded in 2012 and based in Madrid, Spain. GIMIC Ventures and Johnson & Johnson Innovation provided EUR 5 million in venture funding in December 2025 to support preparations for clinical trials and a European Clinical Trial Application.

2Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in